Abstract Title: currently loading...

information currently loading...

Loading ... please wait
timer Loading ... please wait

Free Paper Session 17: AMD & New Drug Treatment & Technology

08:30 - 10:00 | 08 September | Room: Amphitheatre Havane

Back to Previous

08:30A phase 1/2 optogenetic retinal gene therapy clinical trial for non-syndromic retinitis pigmentosa (PIONEER study)
S. Degli Esposti United Kingdom
08:36Efficacy and safety of abicipar compared with ranibizumab in the treatment of neovascular age-related macular degeneration: results from the cedar and sequoia phase 3 clinical trials
E. Souied France
08:42OTS APP: improving the ocular trauma management
H. Ocampo Colombia
08:48Solid lipid nanoparticles improve the diclofenac availability in vitreous after intraocular injection
M. Abrishami Iran, Islamic Republic of
08:54Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor-2 aptamer in animal models of retinal disease
Y. Nakamura Japan
09:00Based on the real-life data of Turkey; one-year results of treatment with anti-vascular endothelial growth factor for exudative age-related macular degeneration in eyes with different baseline visual acuity. Bosphorus retina study group, report 6
M. Ozturk Turkey
09:06One-year efficacy of anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: a meta-analysis and meta-regression
V. Sarao Italy
09:12Correlation of OCT-A and Angiography in the diagnosis and classification of neovascular complexes in nAMD
P. Almuina Varela Spain
09:18Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months
M. Gillies Australia
09:24Cellular resolution retinal pigment epithelium imaging with transscleral optical phase imaging (TOPI)
T. Laforest Switzerland
09:30Safety and efficacy of risuteganib in non-exudative age-related macular degeneration – primary results from a phase 2 study
P. Kaiser United States
09:36Efficacy and treatment burden of intravitreal aflibercept vs. ranibizumab treat-and-extend regimens at 24 months: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison
P. Lanzetta Italy
09:42Analysis of the relationship between anatomic control and visual acuity outcomes with anti-VEGF therapy: a post-hoc analysis of catt study data
M. Singer United States
09:48Extended durability in exudative retinal diseases using a new class of molecules: novel anti-VEGF antibody biopolymer conjugate KSI-301: first-time results of the phase 1b study in patients with wAMD, DME and RVO
P. Dugel United States
Back to Previous

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved